Premium
The Application of Immunotargeting into Cancer Chemotherapy with Carboplatin: in vitro and in vivo Studies
Author(s) -
Ota Yoriko,
Oehr Peter,
Inaba Noriyuki,
Takamizawa Hiroyoshi
Publication year - 1993
Publication title -
asia‐oceania journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 0389-2328
DOI - 10.1111/j.1447-0756.1993.tb00406.x
Subject(s) - carboplatin , in vivo , cancer chemotherapy , in vitro , chemotherapy , intraperitoneal chemotherapy , cancer , pharmacology , oncology , medicine , chemistry , biology , cisplatin , microbiology and biotechnology , ovarian cancer , biochemistry
Anti‐tumor effects of the following 2 cis‐diammin (1, 1‐cyclobutandicarboxylato) platin II (carboplatin, Bristol‐Myers‐Squibb) conjugates were evaluated through both in vitro and in vivo experiments: (1) carboplatin coupled with anti‐cytokeratin monoclonal antibody (MAb), TS1 via carboxymethyl dextran (carboplatin‐carboxymethyl dextran‐TSl), and (2) carboplatin‐carboxymethyl dextran‐avidin targeted to biotiny‐lated TS1. Using l‐ethyl‐3(3‐dimethylaminopropyl)‐carbodiimide and N ‐hydro‐xysuccinimide, carboplatin was conjugated to carboxymethyl dextran, TS1, or avidin, at high molar ratios. The staining positivity of carboplatin‐carboxymethyl dextran‐TSl in indirect immunofluorescence was almost identical to that of the original MAb. The average dose of carboplatin given in each treatment was about 60% of a clinical dose. Regarding cytotoxicity, the free drug showed the strongest effect and the best dose‐dependency in cell lines: HeLa and ZR‐75‐1. An in vivo study giving carbo‐platin‐MAb conjugates or free drug to HeLa tumor bearing nude rats proved that the efficacy of carboplatin‐carboxymethyl dextran‐TSl in HeLa tumor was not greater than that of the free carboplatin.